|
|
| (12 intermediate revisions by 4 users not shown) |
| Line 1: |
Line 1: |
| {{West nile virus}}
| | #redirect [[West nile virus infection medical therapy]] |
| {{CMG}}; {{AE}} {{AL}}
| |
| | |
| ==Overview==
| |
| There is no specific [[antiviral]] treatment for west nile virus infection. Current management of these patients is based on supportive care towards [[symptom]] relief and prevention of [[complications]].
| |
| | |
| ==Medical Therapy==
| |
| ====Supportive care <small><small><small><small>Adapted from CDC<ref name="CDC">{{cite web| url= http://www.cdc.gov/westnile/healthCareProviders/healthCareProviders-TreatmentPrevention.html| title= CDC Treatment and Prevention}}</ref></small></small></small></small>====
| |
| * There is no specific [[antiviral]] therapy indicated in patients with west nile virus infection.
| |
| * Treatment consist of supportive measurements and prevention of complications.
| |
| * In severe cases, patients often need to be hospitalized to receive supportive treatment, such as [[intravenous fluids]], [[analgesics]], and nursing care.
| |
| *Patients with severe meningeal symptoms often require pain control for [[headaches]] and antiemetic therapy and rehydration for associated [[nausea]] and [[vomiting]].
| |
| *Patients with [[encephalitis]] require close monitoring for the development of elevated [[intracranial pressure]] and [[seizures]].
| |
| *Patients with [[encephalitis]] or [[paralysis]] should be monitored for inability to protect their airway.
| |
| *Acute neuromuscular [[respiratory failure]] may develop rapidly and prolonged ventilatory support may be required.
| |
| | |
| ===Medications===
| |
| *There are no guideline-supported medications for the treatment of west nile virus encephalitis or meningitis.<ref name="TunkelGlaser2008">{{cite journal|last1=Tunkel|first1=Allan R.|last2=Glaser|first2=Carol A.|last3=Bloch|first3=Karen C.|last4=Sejvar|first4=James J.|last5=Marra|first5=Christina M.|last6=Roos|first6=Karen L.|last7=Hartman|first7=Barry J.|last8=Kaplan|first8=Sheldon L.|last9=Scheld|first9=W. Michael|last10=Whitley|first10=Richard J.|title=The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America|journal=Clinical Infectious Diseases|volume=47|issue=3|year=2008|pages=303–327|issn=1058-4838|doi=10.1086/589747}}</ref>
| |
| * [[Ribavirin]] has been used in cases of west nile virus [[CNS]] involvement, as it has demonstrated inhibition of the [[virus]] in human neural cells ''in vitro''.<ref>{{Cite journal
| |
| | author = [[I. Jordan]], [[T. Briese]], [[N. Fischer]], [[J. Y. Lau]] & [[W. I. Lipkin]]
| |
| | title = Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells
| |
| | journal = [[The Journal of infectious diseases]]
| |
| | volume = 182
| |
| | issue = 4
| |
| | pages = 1214–1217
| |
| | year = 2000
| |
| | month = October
| |
| | doi = 10.1086/315847
| |
| | pmid = 10979920
| |
| }}</ref><ref>{{Cite journal
| |
| | author = [[S. Ia Loginova]], [[S. V. Borisevich]], [[Iu A. Pashchenko]] & [[V. P. Bondarev]]
| |
| | title = [Ribavirin prophylaxis and therapy of experimental West Nile fever]
| |
| | journal = [[Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] / Ministerstvo meditsinskoi i mikrobiologicheskoi promyshlennosti SSSR]]
| |
| | volume = 54
| |
| | issue = 11-12
| |
| | pages = 17–20
| |
| | year = 2009
| |
| | month =
| |
| | pmid = 20583562
| |
| }}</ref>
| |
| *[[Interferon alfa-2b]] has also shown benefit in ''in vitro'' studies against west nile virus [[CNS]] infection.<ref name="Anderson2002">{{cite journal|last1=Anderson|first1=John F.|title=Efficacy of Interferon -2b and Ribavirin Against West Nile Virus In Vitro|journal=Emerging Infectious Diseases|volume=8|issue=1|year=2002|pages=107–108|issn=10806040|doi=10.3201/eid0801.010252}}</ref>
| |
| *Further studies need to be done to determine the efficacy and safety of [[ribavirin]] and [[interferon alfa-2b]] in west nile virus infection.
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |